BethAnnHellerstedtMD

Oncology • Round Rock, TX

Physician

Join to view full profile

Dr. Hellerstedt is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hellerstedt's full profile

Already have an account?

Office
2410 Round Rock Ave
Ste 150
Round Rock, TX 78681
Phone+1 512-341-8724

Fax+1 512-687-0295

Education & Training

University of MichiganFellowship, Hematology and Medical Oncology, 2000 - 2003
University of MichiganResidency, Internal Medicine, 1997 - 2000
University of Pittsburgh School of MedicineClass of 1997

Certifications & Licensure

TX State Medical License 2003 - 2026
MI State Medical License 2000 - 2004
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook

Clinical Trials

Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer Start of enrollment: 2005 Mar 01
Completed
Not Applicable
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer Start of enrollment: 2007 May 08
Active, not recruiting
Phase 3
S0713: Oxaliplatin, Capecitabine, Cetuximab, and RT Followed By Surgery in Pts W/Stage II or III Rectal Cancer Start of enrollment: 2009 Feb 01
Completed
Phase 2
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2009 Jul 15
Terminated
Phase 3
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi Start of enrollment: 2012 Oct 03
Terminated
Phase 3
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

18 citations
Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung Carcinoma.
Beth A. Hellerstedt, Nicholas J. Vogelzang, Harriet M. Kluger, Christopher A. Yasenchak, Dana T. Aftab
Clinical Lung Cancer. 2019-03-01
1 citations
Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in H...
Frankie A. Holmes, Beth A. Hellerstedt, John Pippen, Svetislava J. Vukelja, Rufus P. Collea
Cancer Medicine. 2018-06-01
19 citations
Incidence and Predictive Factors for Recovery of Ovarian Function in Amenorrheic Women in Their 40s Treated With Letrozole
Lea Krekow, Beth A. Hellerstedt, Rufus P. Collea, Steven Papish, Shrinivas M. Diggikar
Journal of Clinical Oncology. 2016-09-27

Journal Articles

Results of a Phase 2 Placebo-Controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–Small-Cell Lung Carcinoma
Beth A Hellerstedt, Nicholas J Vogelzang, Harriet M Kluger, Christopher A Yasenchak, Michael S Gordon, Primo Lara, Clinical Lung Cancer

Authored Content

Results of a Phase 2 Placebo-Controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–Small-Cell Lung CarcinomaOctober 2018

Press Mentions

Austin’s Top Doctors 2021December 21st, 2020
Dr. Beth Hellerstedt: Personalizing Breast Cancer Care During COVID-19October 19th, 2020
Breast Cancer Awareness Month: Living with Metastatic Breast CancerOctober 14th, 2019

Professional Memberships

American Society of Clinical Oncology - ASCO
Member